BioAlliance Pharma Announces the Initiation of the Phase II Clinical Trial With Validive® in the United States
6/10/2013 10:32:59 AM
Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!
PARIS--(BUSINESS WIRE)--Regulatory News: BioAlliance Pharma SA (Paris:BIO) (Euronext Paris - BIO), a Company dedicated to the development of orphan oncology products and supportive care products, announces the initiation of its Phase II clinical trial evaluating the efficacy and safety of Validive® (clonidine Lauriad®) in the United States in patients with chemoradiation therapy-induced oral mucositis with head and neck cancer, as scheduled in the advancement calendar of the project.
Help employers find you! Check out all the jobs and post your resume.
comments powered by